INSM Q1 2023 Earnings — Insmed Incorporated Revenue & Financial Results | Market Cap Arena

INSMInsmed Incorporated

$31B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$65M+22.8% YoY

Gross Profit

$51M78.8% margin

Operating Income

-$148M-227.2% margin

Net Income

-$160M-245.0% margin

EPS (Diluted)

$-1.17

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

-$146M

Free Cash Flow

-$150M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$1.6B

Stockholders' Equity

-$45M

Cash & Equivalents

$969M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$65M	$53M	+22.8%
Gross Profit	$51M	$41M	+25.6%
Operating Income	-$148M	-$90M	-64.9%
Net Income	-$160M	-$95M	-68.8%

Geographic Segments

UNITED STATES

$49M75%

JAPAN

$13M20%

Europe And The Rest Of The World

$3M5%